Takeaway

• A novel peptide-based T-cell-inducing COVID-19 vaccine candidate, CoVac-1, demonstrated favorable safety and efficacy in cancer and other immunocompromised patients with B-cell deficiency.

Why this matters

• Although approved mRNA COVID-19 vaccines induce a strong immune response against the SARS-CoV-2 virus in the majority of immunocompetent individuals, their efficacy is substantially...